, Tracking Stock Market Picks
Enter Symbol:
Pharmacyclics, Inc. (PCYC) [hlAlert]

up 86.94 %

Pharmacyclics, Inc. (PCYC) rated Outperform by Wells Fargo

Posted on: Friday,  Oct 4, 2013  9:25 AM ET by Wells Fargo

Wells Fargo rated Outperform Pharmacyclics, Inc. (NASDAQ: PCYC) on 10/04/2013, when the stock price was $139.75. Since
then, Pharmacyclics, Inc. has gained 86.94% as of 05/22/2015's recent price of $261.25.
If you would have followed this Wells Fargo's recommendation on PCYC, you would have gained 86.94% of your investment in 595 days.

Pharmacyclics Inc. is a pharmaceutical company developing products to improve upon therapeutic approaches to cancer, atherosclerosis and retinal disease. The company's products are ring-shaped small molecules called texaphyrins. These patented agents are derived from Pharmacyclics' versatile technology platform for designing and synthesizing energy-potentiating drugs. The texaphyrins localize in cancer cells, atherosclerotic plaque and neovasculature, where they can be activated by forms of energy, including X-rays and light to reduce diseased tissue.

The investment research content is provided by Wells Capital Management, a registered investment adviser and wholly owned subsidiary of Wells Fargo Bank, N.A. Our economists’ expertise on domestic markets, and national and global trends, is an important resource to the firm. Wells Capital Management economists are known for their thoughts on investment strategy, macro-economic forecasts and other top-down analysis, and share their views on bonds, midcaps and liquidity management in their publications.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/4/2013 9:25 AM Buy
as of 12/13/2013
1 Week down  -15.52 %
1 Month down  -12.87 %
3 Months down  -22.80 %
1 YTD down  -22.80 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy